Injectable GLP-1s have the strongest evidence for significant, sustained weight loss.For patients who prioritize needle-free treatment or struggle with adherence to strict oral dosing requirements, ODT formulations may be a practical alternative when used under close medical supervision
Effective April 22, 2026, BPC-157 was removed from Category 2 (the bulks substances list flagged as raising significant safety concerns)
Ensure you are at the right dose , following appropriate dietary guidelines , managing food choices , and building sustainable habits that will support long-term success regardless of which medication you use
People with a BMI of 27+ and weight-related conditions You may also be a candidate for Semaglutide if you have other weight-related health conditions and your BMI is between 27 and 29.9
Patients who stop semaglutide regain their lost weight
Biohack Nordic Premium Research Peptides